This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xia, T. Articles by Harrington, W. J. Search for Related Content PubMed PubMed Citation Articles by Xia, T. Articles by Harrington, W. J., Jr.

EBV MicroRNAs in Primary Lymphomas and Targeting of CXCL-11 by ebv-mir-BHRF1-3

¹ The Viral Oncology Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida; ² The Department of Microbiology and Immunology, Curriculum in Genetics and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and ³ The Federal University of Bahia; ⁴ Hospital Aristides Maltez; ⁵ Hospital Martagao Gesteira, Salvador, Bahia, Brazil

Requests for reprints: William J. Harrington, Jr., Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Room 3400, 1475 Northwest 12th Avenue (D8-4), Miami, FL 33136. Phone: 305-243-6611; Fax: 305-243-5885; E-mail: wharring{at}med.miami.edu.

Key Words: lymphoma • EBV • microRNA • latency • Burkitt's

EBV-encoded microRNAs (miRNAs) have been identified and their functions are being studied. The expression pattern of these miRNAs in clinical samples of EBV-associated non–Hodgkin's lymphomas is unknown. We analyzed five primary "endemic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I latency BL lines, a type III latency line, three EBV⁺ primary effusion lymphomas (PEL), and three AIDS-related diffuse large B-cell lymphomas (DLBCL) for expression of EBV-encoded miRNAs. A markedly elevated expression of miRNA BHRF1-3 in type III relative to its parental type I BL line was found. Primary unmanipulated type I BLs and EBV⁺ PELs expressed high levels of BART2 miRNA, whereas DLBCLs expressed both BART2 and BHRF1-3 species. BHRF1-3 miRNA expression inversely correlated with levels of a putative cellular target, the IFN-inducible T-cell attracting chemokine CXCL-11/I-TAC, and suppression of this factor was reversed by transfection of an antisense oligo to the EBV miRNA BHRF1-3. EBV-encoded miRNAs are expressed in primary lymphomas classically linked to the virus and are associated with the viral latency status. Targeted suppression of CXCL-11/I-TAC by a viral-encoded miRNA may serve as an immunomodulatory mechanism in these tumors. [Cancer Res 2008;68(5):1436–42]

This article has been cited by other articles:

				J. L. Umbach and B. R. Cullen The role of RNAi and microRNAs in animal virus replication and antiviral immunity Genes & Dev., May 15, 2009; 23(10): 1151 - 1164. [Abstract] [Full Text] [PDF]

				K. Cosmopoulos, M. Pegtel, J. Hawkins, H. Moffett, C. Novina, J. Middeldorp, and D. A. Thorley-Lawson Comprehensive Profiling of Epstein-Barr Virus MicroRNAs in Nasopharyngeal Carcinoma J. Virol., March 1, 2009; 83(5): 2357 - 2367. [Abstract] [Full Text] [PDF]

				Z. Ghosh, B. Mallick, and J. Chakrabarti Cellular versus viral microRNAs in host-virus interaction Nucleic Acids Res., March 1, 2009; 37(4): 1035 - 1048. [Abstract] [Full Text] [PDF]

				E. Y.-W. Choy, K.-L. Siu, K.-H. Kok, R. W.-M. Lung, C. M. Tsang, K.-F. To, D. L.-W. Kwong, S. W. Tsao, and D.-Y. Jin An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival J. Exp. Med., October 27, 2008; 205(11): 2551 - 2560. [Abstract] [Full Text] [PDF]

				M. L. Gulley and W. Tang Laboratory Assays for Epstein-Barr Virus-Related Disease J. Mol. Diagn., July 1, 2008; 10(4): 279 - 292. [Abstract] [Full Text] [PDF]